Abstract
Antibodies intended for clinical use have been isolated from non-human primates (NHP), chimpanzees (Pan troglodytes) and macaques (Macaca fascicularis and Macaca mulatta), essentially with the use of the phage-display technology. All studies presenting such isolations have been reviewed and presented here, following the main steps of this technology, and advantages and disadvantages of NHP species were analyzed. Optimization of the tolerance of chimeric NHP-human antibodies by germline humanization was mentioned, and the recent alleviation of legal constraints was revealed. The methodology combining the use of phage-displayed libraries built from immunised NHP with germline humanization should be chosen more frequently to develop well-tolerated IgGs, directed against infectious or human antigens.
Keywords: Antibodies, chimpanzee, clinical, humanization, macaque, non-human primates, patent, phage.
Current Drug Discovery Technologies
Title:Isolation of Antibodies From Non-Human Primates for Clinical Use
Volume: 11 Issue: 1
Author(s): Arnaud Avril, Jeffrey W. Froude, Jacques Mathieu, Thibaut Pelat and Philippe Thullier
Affiliation:
Keywords: Antibodies, chimpanzee, clinical, humanization, macaque, non-human primates, patent, phage.
Abstract: Antibodies intended for clinical use have been isolated from non-human primates (NHP), chimpanzees (Pan troglodytes) and macaques (Macaca fascicularis and Macaca mulatta), essentially with the use of the phage-display technology. All studies presenting such isolations have been reviewed and presented here, following the main steps of this technology, and advantages and disadvantages of NHP species were analyzed. Optimization of the tolerance of chimeric NHP-human antibodies by germline humanization was mentioned, and the recent alleviation of legal constraints was revealed. The methodology combining the use of phage-displayed libraries built from immunised NHP with germline humanization should be chosen more frequently to develop well-tolerated IgGs, directed against infectious or human antigens.
Export Options
About this article
Cite this article as:
Avril Arnaud, Froude W. Jeffrey, Mathieu Jacques, Pelat Thibaut and Thullier Philippe, Isolation of Antibodies From Non-Human Primates for Clinical Use, Current Drug Discovery Technologies 2014; 11 (1) . https://dx.doi.org/10.2174/15701638113109990030
DOI https://dx.doi.org/10.2174/15701638113109990030 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lipoxin and Synthetic Lipoxin Analogs: An Overview of Anti- Inflammatory Functions and New Concepts in Immunomodulation
Inflammation & Allergy - Drug Targets (Discontinued) Biosafety of Lentiviral Vectors
Current Gene Therapy Recent Advances in Targeting Viral Proteases for the Discovery of Novel Antivirals
Current Topics in Medicinal Chemistry Midkine: A Promising Molecule for Drug Development to Treat Diseases of the Central Nervous System
Current Pharmaceutical Design SRLVs: A Genetic Continuum of Lentiviral Species in Sheep and Goats with Cumulative Evidence of Cross Species Transmission
Current HIV Research Applications of Gene Therapy to the Treatment of Chronic Pain
Current Gene Therapy Recent Patents on Nucleic Acid-Based Antiviral Therapeutics
Recent Patents on Anti-Infective Drug Discovery Updating the Chemistry and Biology of Cannabinoid CB2 Receptor – Specific Inverse Agonists
Current Topics in Medicinal Chemistry Novel Antiviral Strategies to Combat Human Arenavirus Infections
Current Molecular Medicine Blood-Brain Barrier Transport of Drugs for the Treatment of Brain Diseases
CNS & Neurological Disorders - Drug Targets Altering the Tropism of Lentiviral Vectors through Pseudotyping
Current Gene Therapy Toll-Like Receptors: Sensor Molecules for Detecting Damage to the Nervous System
Current Protein & Peptide Science Biological Activities of Artemisinin Derivatives Beyond Malaria
Current Topics in Medicinal Chemistry Listeria-Based Anti-Infective Vaccine Strategies
Recent Patents on Anti-Infective Drug Discovery Pharmacological Perspectives of Ayurvedic Herbs <i>viz. Alstonia scholaris</i> L., <i>Picrorhiza kurroa, Swertia chirata</i> and <i>Caesalpinia crista</i> Against COVID- 19: A Mini-Review
Mini-Reviews in Organic Chemistry Is there a Rational Approach for Increasing Drug Specificity? Considerations on CNS Target Choice and Validation
Recent Patents on CNS Drug Discovery (Discontinued) Host Innate Immune Responses to Microbial Pathogens
Current Vascular Pharmacology Can Acetylcholinesterase Serve as a Target for Developing More Selective Insecticides?
Current Drug Targets Cognitive Consequences of a Sustained Monocyte Type 1 IFN Response in HIV-1 Infection
Current HIV Research HSV Amplicons: Neuro Applications
Current Gene Therapy